{"id":20458,"date":"2022-12-30T11:13:52","date_gmt":"2022-12-30T05:43:52","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=20458"},"modified":"2023-06-14T09:19:27","modified_gmt":"2023-06-14T03:49:27","slug":"emerging-therapies-for-pd-lid-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment","title":{"rendered":"Need of the Hour: Enhanced Strategies for PD-LID Treatment and Management"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0355a0e54ce\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0355a0e54ce\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment\/#Are_the_shortcomings_answered_for_PD-LID_treatment\" >Are the shortcomings answered for PD-LID treatment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment\/#Reflecting_on_the_upcoming_PD-LID_treatment_options\" >Reflecting on the upcoming PD-LID treatment options<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment\/#Can_gene_therapy_be_the_silver_lining_for_the_PD-LID_treatment_landscape\" >Can gene therapy be the silver lining for the PD-LID treatment landscape?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment\/#Whats_ahead_in_the_PD-LID_treatment_market\" >What\u2019s ahead in the PD-LID treatment market?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Parkinson\u2019s disease (PD) is a degenerative neurological condition primarily affecting middle-aged and older adults and is characterized by tremors, muscular rigidity, and slow, clumsy movement. It is connected to the brain\u2019s basal ganglia atrophy and a lack of the neurotransmitter dopamine. Levodopa is considered a linchpin despite the availability of other agents for reducing the symptoms of Parkinson\u2019s disease. However, prolonged levodopa usage can lead to levodopa-induced dyskinesia (LID).<\/p>\n\n\n\n<p>As per a study by Jose (2000), Parkinson\u2019s disease is an age-related neurodegenerative disorder with an average onset age of 60. In the United States, approximately<strong> 1 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-epidemiology-forecast\">people suffer from Parkinson\u2019s disease<\/a>, and there are <strong>60,000<\/strong> newly diagnosed cases every year. After 5 years of PD-LID treatment, <strong>&gt;50%<\/strong> of patients experience motor fluctuations and dyskinesias.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><strong>According to the latest published \u201c<a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-levodopa-induced-dyskinesia-pd-lid-epidemiology-forecast\">Parkinson\u2019s disease Levodopa-induced dyskinesia Epidemiology<\/a>\u201d report, Parkinson\u2019s disease levodopa-induced dyskinesia (PD-LID) affected around 290,000 people in the US, 250,000 people in EU4 and the UK, and 45,000 in Japan in 2021.<\/strong><\/p>\n<\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-are-the-shortcomings-answered-for-pd-lid-treatment\"><span class=\"ez-toc-section\" id=\"Are_the_shortcomings_answered_for_PD-LID_treatment\"><\/span><strong>Are the shortcomings answered for PD-LID treatment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Although levodopa is the gold standard for treating <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\">Parkinson\u2019s disease patients<\/a>, its prolonged usage can cause levodopa-induced dyskinesia, as there are no validated diagnostic techniques to determine the emergence and progression of levodopa-induced dyskinesia. Patients\u2019 self-assessments are considered to establish the different aspects of dyskinesia and the effects of drugs. Despite all the advances, the pathogenesis of dyskinesia induced by levodopa remains unclear. It requires research to illuminate the pathomechanism and assist the pharma players in establishing new Parkinson\u2019s disease levodopa-induced dyskinesia treatment options and related symptoms.<\/p>\n\n\n\n<p>Due to the unclear pathomechanism, PD-LID management remains a matter of concern as the current strategies revolve around dopamine stimulation, levodopa-sparing strategies, and nondopaminergic add-ons. Though therapies like <strong>GOCOVRI (PD-LID) and NOURIANZ (wearing off)<\/strong> are available for PD-LID management, none improve daily living activities, enhance the quality of life, or decrease caregiver burden. Furthermore, the appearance of levodopa-induced dyskinesia in Parkinson\u2019s disease patients creates an additional economic burden. Compared to <a href=\"https:\/\/www.delveinsight.com\/report-store\/levodopa-induced-dyskinesia-lid-pipeline-insight\">patients without levodopa-induced dyskinesia<\/a>, those with levodopa-induced dyskinesia have a <strong>78%<\/strong> increase in PD-related treatment expenses and a 29% increase in overall treatment costs. Hence, advancements are required for PD-LID treatment that pave the way for potential therapies to enter the PD-LID treatment market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Reflecting_on_the_upcoming_PD-LID_treatment_options\"><\/span><strong>Reflecting on the upcoming PD-LID treatment options<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-levodopa-induced-dyskinesia-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204245\/PD-LID-Pipeline-Assessment.png\" alt=\"PD-LID Pipeline Assessment\" class=\"wp-image-20465\" width=\"954\" height=\"461\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204245\/PD-LID-Pipeline-Assessment.png 954w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204245\/PD-LID-Pipeline-Assessment-300x145.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204245\/PD-LID-Pipeline-Assessment-150x72.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204245\/PD-LID-Pipeline-Assessment-768x371.png 768w\" sizes=\"(max-width: 954px) 100vw, 954px\" \/><\/a><figcaption class=\"wp-element-caption\"><strong>Emerging Therapies for PD-LID Treatment<\/strong><\/figcaption><\/figure>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-levodopa-induced-dyskinesia-market\">PD-LID market<\/a> was valued at around <strong>USD 1,400<\/strong> million in 2019 and is expected to reach <strong>USD 2,300<\/strong> million by 2032, growing at a <strong>CAGR of<\/strong> <strong>3.6% <\/strong>during the study period. <strong>KETARX (PharmaTher), NLX-112 (Neurolixis SAS\/Gala laboratories), JM-010 (Bukwang Pharmaceutical\/Contera Pharma), AV-101 (Vistagen), Mesdopetam (Ipsen Pharma), XADAGO (Newron Pharmaceuticals\/Zambon Pharmaceuticals) and CPL500036 (Celon Pharma SA)<\/strong> are investigating their respective candidates for PD-LID treatment and management in the 7MM. Several late-stage assets with distinct MoA are being developed to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-levodopa-induced-dyskinesia-pd-lid-epidemiology-forecast\">PD-LID patients<\/a> and are expected to enter the 7MM PD-LID treatment market in the next few years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Can_gene_therapy_be_the_silver_lining_for_the_PD-LID_treatment_landscape\"><\/span><strong>Can gene therapy be the silver lining for the PD-LID treatment landscape?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As PD-LID demands more advancements to bridge the gap between research and PD-LID treatment, more studies are being conducted to understand the disease and establish PD-LID treatment options. Research is underway to understand whether the specific calcium channel in the brain results in dyskinesia; however, it is unknown if blocking or silencing this channel can reduce dyskinesia. The experimental model of PD-LID has shown promising results using gene therapy, which enables new genetic information to reduce the number of channels. The positive results from the preliminary data have established a belief that \u2018gene silencing\u2019 could relieve the symptoms of PD-LID and potentially slows the disease progression. Given the favorable preliminary data, the gene therapy approach could be a boon for PD-LID patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Whats_ahead_in_the_PD-LID_treatment_market\"><\/span><strong>What\u2019s ahead in the PD-LID treatment market?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The current PD-LID treatment landscape is based on discontinuing, reducing, or adjusting the amount of dopamine given to patients. Furthermore, different approaches and strategies are personalized through trial and error. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-levodopa-induced-dyskinesia-market\">PD-LID treatment market<\/a> offers these players numerous opportunities to capitalize on the untapped PD-LID treatment market. Although the field is quite active, with numerous trials underway to treat patients with PD-LID, ongoing efforts are required to develop novel PD-LID treatment drugs that are more effective and less toxic. However, more research is needed to develop <a href=\"https:\/\/www.delveinsight.com\/report-store\/levodopa-induced-dyskinesia-lid-pipeline-insight\">drugs to treat dyskinesia in Parkinson&#8217;s disease patients<\/a> taking levodopa. As there is only one approved pharmaceutical PD-LID treatment across the entire landscape, any significant advancement in this direction is expected to have a tectonic impact on the existing PD-LID treatment market scenario during our forecast period (2022\u20132032).<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-levodopa-induced-dyskinesia-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204158\/pd-lid-market-outlook-1024x256.png\" alt=\"PD-LID Market Outlook\" class=\"wp-image-20464\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204158\/pd-lid-market-outlook-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204158\/pd-lid-market-outlook-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204158\/pd-lid-market-outlook-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204158\/pd-lid-market-outlook-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204158\/pd-lid-market-outlook-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204158\/pd-lid-market-outlook-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29204158\/pd-lid-market-outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1672326218712\"><strong class=\"schema-faq-question\"><strong>1. What is LID in Parkinson&#8217;s?<\/strong><\/strong> <p class=\"schema-faq-answer\">LID is a type of dyskinesia caused by the drug levodopa (l-DOPA), which is used to treat Parkinson&#8217;s disease. It frequently includes hyperkinetic movements such as chorea, dystonia, and athetosis. There are three clinical variants of PD-LID: peak-dose dyskinesia, off-period dystonia, and diphasic dyskinesias; they commonly present as chorea or choreoathetosis, but myoclonus, akathisia, ballism, and other abnormal movements have also been described.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1672326240135\"><strong class=\"schema-faq-question\"><strong>2. What are the Parkinson\u2019s disease symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">Parkinson&#8217;s disease signs and symptoms can vary from person to person. Early symptoms may be subtle and go unnoticed. Parkinson&#8217;s disease symptoms typically begin on one side of the body and worsen on that side, even after symptoms begin to affect limbs on both sides. Common Parkinson&#8217;s disease symptoms include tremors, slowed movement, speech changes, writing changes, rigid muscles, and others.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1672326254160\"><strong class=\"schema-faq-question\"><strong>3. What are the current Parkinson&#8217;s disease treatment options?<\/strong><\/strong> <p class=\"schema-faq-answer\">Levodopa is the most effective Parkinson&#8217;s disease treatment; however, long-term use is complicated by LID, which disables motor fluctuations and involuntary movements. Despite significant progress, the pathogenesis of LID remains unknown. There are currently no validated, quantitative, or qualitative diagnostic techniques to assess the emergence and progression of LID in Parkinson&#8217;s disease patients.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1672326269945\"><strong class=\"schema-faq-question\"><strong>4. How many pharma companies are working in the PD-LID treatment market?<\/strong><\/strong> <p class=\"schema-faq-answer\">Key players in the global PD-LID treatment market include PharmaTher Inc., Neurolixis SAS\/Gala laboratories, Bukwang Pharmaceutical\/Contera Pharma, VistaGen, Ipsen Pharma, and Newron Pharmaceuticals\/Zambon Pharmaceuticals. The expected entry of promising agents, including KETARX, NLX-112, JM-010, AV-101, Mesdopetam, and XADAGO, can transform the current standard of care and PD-LID treatment market during the forecast period.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Parkinson\u2019s disease (PD) is a degenerative neurological condition primarily affecting middle-aged and older adults and is characterized by tremors, muscular rigidity, and slow, clumsy movement. It is connected to the brain\u2019s basal ganglia atrophy and a lack of the neurotransmitter dopamine. Levodopa is considered a linchpin despite the availability of other agents for reducing the [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":20459,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":4,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[16836,20099,1826,6833,3422,20096,20098,20097],"industry":[17225],"therapeutic_areas":[17245],"class_list":["post-20458","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-levodopa","tag-levodopa-induced-dyskinesia","tag-parkinsons-disease","tag-parkinsons-disease-market","tag-parkinsons-disease-therapeutic-market","tag-pd-lid","tag-pd-lid-market","tag-pd-lid-treatment","industry-pharmaceutical","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Watch Out for Most Promising Therapies in Pipeline for PD-LID Treatment<\/title>\n<meta name=\"description\" content=\"The PD-LID treatment space is changing as key companies are evaluating lead assets in different clinical stages to improve therapeutic market\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Watch Out for Most Promising Therapies in Pipeline for PD-LID Treatment\" \/>\n<meta property=\"og:description\" content=\"The PD-LID treatment space is changing as key companies are evaluating lead assets in different clinical stages to improve therapeutic market\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-30T05:43:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T03:49:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29203851\/emerging-therapies-for-pd-lid-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Watch Out for Most Promising Therapies in Pipeline for PD-LID Treatment","description":"The PD-LID treatment space is changing as key companies are evaluating lead assets in different clinical stages to improve therapeutic market","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment","og_locale":"en_US","og_type":"article","og_title":"Watch Out for Most Promising Therapies in Pipeline for PD-LID Treatment","og_description":"The PD-LID treatment space is changing as key companies are evaluating lead assets in different clinical stages to improve therapeutic market","og_url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-12-30T05:43:52+00:00","article_modified_time":"2023-06-14T03:49:27+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29203851\/emerging-therapies-for-pd-lid-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment","url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment","name":"Watch Out for Most Promising Therapies in Pipeline for PD-LID Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29203851\/emerging-therapies-for-pd-lid-treatment.png","datePublished":"2022-12-30T05:43:52+00:00","dateModified":"2023-06-14T03:49:27+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The PD-LID treatment space is changing as key companies are evaluating lead assets in different clinical stages to improve therapeutic market","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326218712"},{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326240135"},{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326254160"},{"@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326269945"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29203851\/emerging-therapies-for-pd-lid-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29203851\/emerging-therapies-for-pd-lid-treatment.png","width":772,"height":482,"caption":"emerging-therapies-for-pd-lid-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326218712","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326218712","name":"1. What is LID in Parkinson's?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"LID is a type of dyskinesia caused by the drug levodopa (l-DOPA), which is used to treat Parkinson's disease. It frequently includes hyperkinetic movements such as chorea, dystonia, and athetosis. There are three clinical variants of PD-LID: peak-dose dyskinesia, off-period dystonia, and diphasic dyskinesias; they commonly present as chorea or choreoathetosis, but myoclonus, akathisia, ballism, and other abnormal movements have also been described.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326240135","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326240135","name":"2. What are the Parkinson\u2019s disease symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Parkinson's disease signs and symptoms can vary from person to person. Early symptoms may be subtle and go unnoticed. Parkinson's disease symptoms typically begin on one side of the body and worsen on that side, even after symptoms begin to affect limbs on both sides. Common Parkinson's disease symptoms include tremors, slowed movement, speech changes, writing changes, rigid muscles, and others.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326254160","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326254160","name":"3. What are the current Parkinson's disease treatment options?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Levodopa is the most effective Parkinson's disease treatment; however, long-term use is complicated by LID, which disables motor fluctuations and involuntary movements. Despite significant progress, the pathogenesis of LID remains unknown. There are currently no validated, quantitative, or qualitative diagnostic techniques to assess the emergence and progression of LID in Parkinson's disease patients.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326269945","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/emerging-therapies-for-pd-lid-treatment#faq-question-1672326269945","name":"4. How many pharma companies are working in the PD-LID treatment market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Key players in the global PD-LID treatment market include PharmaTher Inc., Neurolixis SAS\/Gala laboratories, Bukwang Pharmaceutical\/Contera Pharma, VistaGen, Ipsen Pharma, and Newron Pharmaceuticals\/Zambon Pharmaceuticals. The expected entry of promising agents, including KETARX, NLX-112, JM-010, AV-101, Mesdopetam, and XADAGO, can transform the current standard of care and PD-LID treatment market during the forecast period.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/12\/29203851\/emerging-therapies-for-pd-lid-treatment-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Levodopa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">levodopa induced dyskinesia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapeutic market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-LID<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-LID market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">PD-LID Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Levodopa<\/span>","<span class=\"advgb-post-tax-term\">levodopa induced dyskinesia<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease market<\/span>","<span class=\"advgb-post-tax-term\">Parkinson\u2019s disease therapeutic market<\/span>","<span class=\"advgb-post-tax-term\">PD-LID<\/span>","<span class=\"advgb-post-tax-term\">PD-LID market<\/span>","<span class=\"advgb-post-tax-term\">PD-LID Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Dec 30, 2022","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Dec 30, 2022 11:13 am","modified":"Updated on Jun 14, 2023 9:19 am"},"featured_img_caption":"emerging-therapies-for-pd-lid-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=20458"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/20458\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/20459"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=20458"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=20458"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=20458"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=20458"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=20458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}